InvestorsHub Logo

jtsmgoblue

09/16/19 3:01 PM

#210013 RE: McMagyar #210000

Very good point.

Refer to SRPT and the impact that the DMD families had on the FDA 3 years ago in granting approval for their controversial drug. Families count, must count and must have influence in the archaic FDA approval process. True “Right to Try” can’t happen soon enough.

Patience as we climb to far greater heights.

falconer66a

09/16/19 3:51 PM

#210035 RE: McMagyar #210000

Rett World Tiny, Compared to Parkinson’s and Alzheimer’s

The word will explode through Rett Syndrome population.


Have an acquaintance, whose life has been so severely complicated by caring for a Rett daughter. She and her husband would want Anavex treatment just as soon as it could be prescribed for their daughter. In fact, there is no useful treatment presently. Indeed, the word of this Anavex success is, at this moment, coursing through the connected Rett community.

Just as it will when similar results appear from either the Parkinson’s or Alzheimer’s trials. When that happens, hundreds of family members will be calling their Congressional contacts, asking why this drug is not immediately available. A resident at 1600 Pennsylvania Ave Nw, Washington, DC 20500, will be getting hundreds of phone calls and emails asking the same question.

Inasmuch as there have been no disqualifying adverse events (side effects) in any human ingestion of Anavex 2-73, it will be interesting to ponder the explanations of any approval tardiness. “We don’t know if the drug actually works.” “We aren’t sure, yet of its safety.” Hollow pronouncements, entirely.